These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 30602182

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Inhaled therapies in COPD - all patients on fixed triple?].
    Watz H.
    Dtsch Med Wochenschr; 2021 Apr; 146(7):471-473. PubMed ID: 33780994
    [Abstract] [Full Text] [Related]

  • 26. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
    Calzetta L, Matera MG, Cazzola M.
    Eur J Pharmacol; 2015 Aug 15; 761():168-73. PubMed ID: 25981302
    [Abstract] [Full Text] [Related]

  • 27. Common lung conditions: chronic obstructive pulmonary disease.
    Delzell JE.
    FP Essent; 2013 Jun 15; 409():23-31. PubMed ID: 23767419
    [Abstract] [Full Text] [Related]

  • 28. [Medication management of COPD].
    Gueçamburu M, Zysman M.
    Rev Prat; 2024 Jan 15; 74(1):7-12. PubMed ID: 38329243
    [Abstract] [Full Text] [Related]

  • 29. Triple Therapy in COPD: What We Know and What We Don't.
    Calverley PMA, Magnussen H, Miravitlles M, Wedzicha JA.
    COPD; 2017 Dec 15; 14(6):648-662. PubMed ID: 29120273
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E.
    Respir Med; 2018 Sep 15; 142():73-80. PubMed ID: 30170806
    [Abstract] [Full Text] [Related]

  • 32. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
    Miravitlles M, D'Urzo A, Singh D, Koblizek V.
    Respir Res; 2016 Sep 10; 17(1):112. PubMed ID: 27613392
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A, Zanardi E, Poletti V, Cazzola M.
    Int J Chron Obstruct Pulmon Dis; 2015 Sep 10; 10():1383-92. PubMed ID: 26229457
    [Abstract] [Full Text] [Related]

  • 36. [Chronic obstructive pulmonary disease: the right treatment for the right patient].
    Olschewski H, Buhl R, Funk GC, Valipour A, Vogelmeier CF.
    Internist (Berl); 2021 Jun 10; 62(6):679-685. PubMed ID: 33860810
    [Abstract] [Full Text] [Related]

  • 37. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M, Molimard M.
    Pulm Pharmacol Ther; 2010 Aug 10; 23(4):257-67. PubMed ID: 20381630
    [Abstract] [Full Text] [Related]

  • 38. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations.
    Katajisto M, Koskela J, Lindqvist A, Kilpeläinen M, Laitinen T.
    Respir Med; 2015 Oct 10; 109(10):1320-5. PubMed ID: 26298024
    [Abstract] [Full Text] [Related]

  • 39. Respiratory Conditions: Chronic Obstructive Pulmonary Disease.
    Barstow C, Forbes D.
    FP Essent; 2019 Nov 10; 486():26-32. PubMed ID: 31710455
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.